An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Inclusion Criteria: * Patients who completed 104 weeks of study WA19977 with at least a JIA ACR30 clinical response to RoActemra/Actemra and no serious adverse event or adverse event * Written informed consent obtained from patient if patient is 18 years of age and older, or if under the age of 18 years from parents or legal guardian Exclusion Criteria: * Patient did not benefit from RoActemra/Actemra therapy in study WA19977 * Treatment with any investigational drug since the last administration of study drug in the core study WA19977 * Patients developed any other autoimmune rheumatic disease other than the permitted JIA subsets * Any significant medical or surgical condition that would jeopardize patient's safety * Current serious uncontrolled concomitant disease or infection